1-20 of 22
Authors: Boris Freidlin
Save search
Sort by
Journal Article

Dose optimization during drug development: whether and when to optimize

PDF
Edward L Korn and others
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 5, May 2023, Pages 492–497, https://doi.org/10.1093/jnci/djac232
Published: 19 December 2022
Journal Article

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

PDF
Patricia M LoRusso and Boris Freidlin
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 2, February 2023, Pages 122–124, https://doi.org/10.1093/jnci/djac212
Published: 30 November 2022
Journal Article

Augmenting randomized clinical trial data with historical control data: Precision medicine applications

PDF
Boris Freidlin and Edward L Korn
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 14–20, https://doi.org/10.1093/jnci/djac185
Published: 26 September 2022
Journal Article

Clinical Benefit Scales and Trial Design: Some Statistical Issues

PDF
Edward L Korn and others
JNCI: Journal of the National Cancer Institute, Volume 114, Issue 9, September 2022, Pages 1222–1227, https://doi.org/10.1093/jnci/djac099
Published: 18 May 2022
Journal Article

A Problematic Biomarker Trial Design

PDF
Boris Freidlin and Edward L Korn
JNCI: Journal of the National Cancer Institute, Volume 114, Issue 2, February 2022, Pages 187–190, https://doi.org/10.1093/jnci/djab144
Published: 21 July 2021
Journal Article

Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?

PDF
Boris Freidlin and others
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 8, August 2020, Pages 773–778, https://doi.org/10.1093/jnci/djz240
Published: 23 December 2019
Journal Article

Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008–2017

PDF
Jared C Foster and others
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 2, February 2020, Pages 128–135, https://doi.org/10.1093/jnci/djz193
Published: 23 September 2019
Journal Article

Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?

PDF
Boris Freidlin and Edward L. Korn
JNCI: Journal of the National Cancer Institute, Volume 109, Issue 9, September 2017, djx146, https://doi.org/10.1093/jnci/djx146
Published: 08 August 2017
Journal Article

Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements

PDF
Edward L. Korn and Boris Freidlin
JNCI: Journal of the National Cancer Institute, Volume 109, Issue 6, June 2017, djx013, https://doi.org/10.1093/jnci/djx013
Published: 17 March 2017
Journal Article

RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval

PDF
Boris Freidlin and Edward L. Korn
JNCI: Journal of the National Cancer Institute, Volume 108, Issue 3, March 2016, djv430, https://doi.org/10.1093/jnci/djv430
Published: 24 February 2016
Journal Article

Design Issues in Randomized Clinical Trials of Maintenance Therapies

PDF
Boris Freidlin and others
JNCI: Journal of the National Cancer Institute, Volume 107, Issue 11, November 2015, djv225, https://doi.org/10.1093/jnci/djv225
Published: 18 August 2015
Journal Article

Response Get access

PDF
Boris Freidlin and Edward L. Korn
JNCI: Journal of the National Cancer Institute, Volume 106, Issue 4, April 2014, dju059, https://doi.org/10.1093/jnci/dju059
Published: 21 March 2014
Journal Article

A Model Too Far Get access

PDF
Boris Freidlin and Edward L. Korn
JNCI: Journal of the National Cancer Institute, Volume 106, Issue 2, February 2014, djt368, https://doi.org/10.1093/jnci/djt368
Published: 06 January 2014
Journal Article

Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers Get access

PDF
Mei-Yin C. Polley and others
JNCI: Journal of the National Cancer Institute, Volume 105, Issue 22, 20 November 2013, Pages 1677–1683, https://doi.org/10.1093/jnci/djt282
Published: 17 October 2013
Journal Article

NCI–RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers Get access

PDF
Yaacov Richard Lawrence and others
JNCI: Journal of the National Cancer Institute, Volume 105, Issue 1, 2 January 2013, Pages 11–24, https://doi.org/10.1093/jnci/djs472
Published: 29 December 2012
Journal Article

Re: Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction Get access

PDF
Richard M. Simon and Boris Freidlin
JNCI: Journal of the National Cancer Institute, Volume 103, Issue 5, 2 March 2011, Page 445, https://doi.org/10.1093/jnci/djq552
Published: 12 January 2011
Journal Article

Randomized Clinical Trials With Biomarkers: Design Issues Get access

PDF
Boris Freidlin and others
JNCI: Journal of the National Cancer Institute, Volume 102, Issue 3, 3 February 2010, Pages 152–160, https://doi.org/10.1093/jnci/djp477
Published: 03 February 2010
Journal Article

Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect Get access

PDF
Wenyu Jiang and others
JNCI: Journal of the National Cancer Institute, Volume 99, Issue 13, 4 July 2007, Pages 1036–1043, https://doi.org/10.1093/jnci/djm022
Published: 04 July 2007
Journal Article

Response: Re: Trends in Reported Incidence of Primary Malignant Brain Tumors in Children in the United States Get access

Malcolm A. Smith and others
JNCI: Journal of the National Cancer Institute, Volume 91, Issue 11, 2 June 1999, Pages 973B–974, https://doi.org/10.1093/jnci/91.11.973b
Published: 02 June 1999
Journal Article

Responses - Re: Trends in Reported Incidence of Primary Malignant Brain Tumors in Children in the United States Get access

PDF
Malcolm A. Smith and others
JNCI: Journal of the National Cancer Institute, Volume 91, Issue 7, 7 April 1999, Page 649, https://doi.org/10.1093/jnci/91.7.649
Published: 07 April 1999